IndustryCompany release

Eocene unit and Barcode Nanotech develop tumour-targeted nanoparticle form of Aramchol for liver and GI cancers

EoCene Ltd. (EOCN) · Mon 16 Nov 2026

Galmed R&D, a subsidiary of Eocene, says a new lipid nanoparticle formulation of Aramchol is designed to reach the tumour microenvironment; the work is preclinical.

Eocene Ltd. reported on 16 November 2026 that its subsidiary Galmed R&D has developed a new lipid nanoparticle formulation of Aramchol, working with Barcode Nanotech.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): EoCene Ltd. ↗

Article written by VigiEye from the official source (EoCene Ltd.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →